The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

Matthew D. Blunt, Matthew J. Carter, Marta Larrayoz, Lindsay D Smith, Maria Aguilar-Hernandez, Kerry L Cox, Thomas Tipton, Mark Reynolds, Sarah Murphy, Elizabeth Lemm, Samantha Dias, Andrew Duncombe, Jonathan C. Strefford, Peter W. M. Johnson, Francesco Forconi, Freda K Stevenson, Graham Packham, Mark S. Cragg, Andrew J. Steele

1 Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom SO16 6YD
2 Instituto Nacional de Pediatría Insurgentes Sur 3700-C Col. Insurgentes Cuicuilco C.P. 04530 Mexico
3 Hematology department, Southampton General Hospital, Southampton, United Kingdom SO16 6YD
4 Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton

*these authors contributed equally

Running title: Dual PI3K/mTOR inhibition in CLL

Scientific category: Lymphoid neoplasia

Corresponding author: Andrew J. Steele, Cancer Sciences Unit, Somers Building (Mailpoint 824), Southampton General Hospital, Tremona Rd, Southampton SO16 6YD, UK

E-mail: a.steele@soton.ac.uk

Phone: +44(0)2381205170

Fax: +44(0)23805152

Text word count: 3983
Abstract word count: 200
Number of Figures: 7
KEY POINTS:

- PF-04691502 induces potent apoptosis in CLL cells and suppresses pro-survival anti-IgM signaling and CXCL12-induced migration.
- PF-04691502 displays powerful anti-tumor effects in vivo in the Eµ-TCL1 mouse model.

ABSTRACT

Current treatment strategies for CLL involve a combination of conventional chemotherapeutics, monoclonal antibodies and targeted signaling inhibitors. However, CLL remains largely incurable with drug resistance and treatment relapse a common occurrence; leading to the search for novel treatments. mTOR specific inhibitors have been previously assessed but their efficacy is limited due to a positive feedback loop via mTORC2, resulting in activation of pro-survival signaling. Here we show that the dual PI3K/mTOR inhibitor PF-04691502 does not induce an mTORC2 positive feedback loop similar to other PI3K inhibitors but does induce substantial anti-tumor effects. PF-04691502 significantly reduced survival coincident with the induction of Noxa and Puma, independently of IGHV mutational status, CD38 and ZAP-70 expression. PF-04691502 inhibited both anti-IgM induced signaling and overcame stroma-induced survival signals as well as migratory stimuli from CXCL12. Equivalent in vitro activity was seen in the Eµ-TCL-1 murine model of CLL in vivo, PF-04691502 treatment of tumor-bearing animals resulted in a transient lymphocytosis, followed by a clear reduction in tumor in the blood, bone marrow, spleen and lymph nodes. These data indicate that PF-04691502 or other dual PI3K/mTOR inhibitors in development may prove efficacious for the treatment of CLL, increasing our armamentarium to successfully manage this disease.
INTRODUCTION

Chronic Lymphocytic Leukemia (CLL) is characterized by the accumulation of CD5⁺CD19⁺ cells in the peripheral blood, lymph nodes and bone marrow. Several prognostic markers are associated with progressive disease; these include unmutated immunoglobulin heavy chain variable regions (IGHV) and high expression of CD38 and ZAP-70. Current treatment strategies involve the combination of fludarabine, cyclophosphamide and rituximab, however CLL largely remains incurable with drug resistance and treatment relapse a common occurrence.

Recently, inhibitors targeting key signaling molecules such as BTK (ibrutinib) and PI3K (idelalisib) have been approved due to exceptional clinical responses. In this regard, the PI3K/mTOR pathway is particularly attractive because it is activated upon ligation of various chemokine and cytokine receptors expressed by CLL cells as well as following B cell receptor (BCR) engagement. Class 1 PI3Ks are divided into Class 1A (PI3Kα, PI3Kβ and PI3Kδ) and Class 1B (PI3Kγ) isoforms. The expression of PI3Kδ and PI3Kγ is largely restricted to leukocytes, whilst the expression of PI3Kα and PI3Kβ is ubiquitous. PI3Kδ and PI3Kγ have crucial roles in a plethora of leukocyte functions including proliferation, antibody secretion, survival, migration and ROS generation. Functional redundancy between PI3K isoforms is evident and supported by the fact that multiple isoforms require inhibition to fully reverse the neutrophil survival induced by GM-CSF. PI3K exists in a complex signaling network with multiple partners including those regulating mTOR. mTOR-complex-1 (mTORC1) is a serine/threonine kinase activated downstream of PI3K which controls protein translation, growth and proliferation in part via modulation of S6 ribosomal subunit activity. In contrast, mTOR complex 2 (mTORC2) phosphorylates AKT and is required for maximal activation of AKT (Supplementary Figure 1A and B).

PI3K signaling is known to be overactive in CLL with patients with unmutated IGHV having increased PI3K gene expression compared to patients with mutated IGHV. The PI3Kδ selective inhibitor Idelalisib has been approved by the FDA to treat CLL patients with relapsed disease in combination with rituximab. Idelalisib inhibits chemokine- and BCR-induced signaling and sensitizes CLL cells to standard genotoxic agents. In patients, Idelalisib has a dual mechanism of action: 1) directly reducing CLL cell viability; and 2) disrupting stromal cell interactions and releasing CLL cells from their protective microenvironments into the blood, where they are more susceptible to chemotherapy-induced apoptosis. However single isoform inhibitors against PI3Kα/β/δ and pan-class1 PI3K inhibitors in CLL cells have all been reported to induce apoptosis. Pharmacological inhibition of mTOR induces cell cycle arrest and apoptosis in CLL cells, however prolonged
inhibition of mTOR is known to disrupt negative feedback loops and cause increased AKT\textsuperscript{S473} activation in other malignancies.\textsuperscript{27,28}

Given the important role of both PI3K and mTOR in CLL cell survival, the dual pharmacological inhibition of both Class 1 PI3K and mTOR signaling may offer new therapeutic potential, with the possibility of deeper remissions or as an alternative following resistance to idelalisib. PF-04691502 is a potent selective dual Class 1 pan-PI3K/mTOR inhibitor\textsuperscript{29} shown to inhibit tumor growth and to promote apoptosis in solid tumors.\textsuperscript{29-33} PF-04691502 inhibits (IC\textsubscript{50}) PI3K\textsubscript{δ} 1.6nM(Ki), PI3K\textsubscript{α} 1.8nM(Ki), PI3K\textsubscript{γ} 1.9nM(Ki), PI3K\textsubscript{β} 2.1nM(Ki) and in cells has shown IC\textsubscript{50} values of 3.8nM and 7.5nM for P-AKT\textsuperscript{S473} and P-AKT\textsuperscript{T308}, respectively.\textsuperscript{29} During phase I clinical trials, PF-04691502 was shown to have a similar safety profile to other PI3K inhibitors.\textsuperscript{34}

In this study we showed in primary CLL cells that PF-04691502 induced caspase-dependent apoptosis. In contrast, little effect on the viability of normal B and T lymphocytes was evident. BCR and CXCR4 stimulated signaling was inhibited by PF-04691502 and chemokine mediated motility was potently reduced. Similarly impressive anti-tumor effects were seen with the Eμ-TCL1 murine CLL-like cells \textit{in vitro} and \textit{in vivo}. Together these data indicate that concomitant targeting of mTOR and PI3K is a powerful approach for treating CLL.

**MATERIALS AND METHODS**

**Patients and cells**

Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria.\textsuperscript{35} Forty-nine CLL isolates were studied following informed written consent in accordance with ethics committee approvals under the declaration of Helsinki (reference 228/02/t) (Supplementary Table 1). Procedures for the isolation of malignant cells and the determination of their purity have been described previously.\textsuperscript{36} All isolates contained >90% CD19\textsuperscript{+}CD5\textsuperscript{+} cells. Normal B and T lymphocytes from peripheral blood were taken from healthy age-matched controls as previously described.\textsuperscript{37}

**Reagents**

Tissue culture materials were from life technologies (Paisley, UK). ZVAD.fmK was from Enzo life sciences (Exeter, UK). PF-04691502 was provided by Pfizer Inc. and purchased from Selleckchem for \textit{in vivo} studies (Houston USA). Idelalisib, BYL719, Everolimus, GSK2636771, and AS-605240 and were from Selleckchem (Houston, USA). Annexin-V was from the Southampton CR-UK core proteomics
facility. Anti-IgM was from Cambridge Bioscience (Cambridge, UK) and CXCL12 from Miltenyi (Bisley, UK). HFFF2 cells were a kind gift from Prof. Thomas (University of Southampton).

**Cell culture and protein extraction**

CLL cell culture and protein extraction for immunoblotting were as previously described.\(^{38,39}\) Soluble anti-IgM was used at 20µg/ml, bead bound immobilised anti-IgM was added at 2:1 ratio, bead:CLL cell. Densitometry of immunoblots are depicted in Supplementary Figures 6 and 7.

**Gel electrophoresis and Immunoblotting**

Proteins were separated on 12% polyacrylamide gels (LifeTechnologies, Paisley Scotland), transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) and probed with antibodies listed in Supplementary Table 2. Bands were detected by incubation with HRP-linked secondary antibodies (Dako), enhanced chemiluminescence reagents (Thermo Scientific, Rockford, IL) and visualised using the ChemiDoc-It imaging system (UVP). Band intensities were quantified using ImageJ.

**Viability assays**

CLL cells were treated with PF-04691502 for 24h and viability assessed by Annexin V-FITC and propidium iodide (PI) negativity as previously described.\(^{39}\) Fifty percent inhibitory concentration values (IC\(_{50}\)) were measured using CalcuSyn software (Biosoft, Cambridge). Peripheral blood mononuclear cells from normal donors were plated at 1x10\(^6\)cells/ml, treated with PF-04691502 for 24h and normal T and B cells labelled with APC conjugated anti-CD3 or anti-CD19 respectively, in combination with Annexin V-FITC/PI.\(^{37}\)

**Eµ-TCL1 experiments**

In vitro analysis using Eµ-TCL1 cells were performed at 2.5 x10\(^6\) cells/ml. For in vivo experiments, 1x10\(^7\) Eµ-TCL1 leukemia cells were given by intra-peritoneal injection to congenic, age-matched female C57BL/6 mice, n= 7 per group. Leukemic burden was assessed by tail bleeding, and monitoring total lymphocyte counts and the percentage of CD5\(^+\)B220\(^+\) cells by flow cytometry. PF-04691502 was administered in 0.5% methylcellulose by oral gavage at either 5 or 10mg/kg/day. Animals were sacrificed and organs harvested for further analysis. Total organ tumor burden was calculated by CD5\(^+\)B220\(^+\) flow cytometry using quanti-bright counting beads (Life Technologies, UK).
RESULTS

mTOR inhibition of CLL cells augments AKT\textsuperscript{S473} signaling

Previous studies in other tumor systems have shown that inhibition of mTOR with everolimus/rapamycin results in augmentation of the mTORC2 target, AKT\textsuperscript{S473}.\textsuperscript{27,28} Here we show that this also occurs in CLL cells both in resting conditions and more effectively following BCR engagement with soluble anti-IgM antibodies (Figure 1A and 1B) with the expected effects on the mTOR target phosphorylated (p)S6 kinase (pS6K) (Figure 1C). In contrast, the dual PI3K/mTOR inhibitor PF-04691502 does not induce hyperphosphorylation of AKT\textsuperscript{S473} and inhibits the pathway as shown with other PI3K inhibitors (Supplementary Figure 1C). Phosphorylated-S6K was completely abrogated with PF-04691502, whilst phosphorylated S6 ribosomal protein (pS6\textsuperscript{S235/236}) is regulated by both the MAPK and PI3K/mTOR signalling pathways and was therefore only partially affected by both everolimus and PF-04691502 (Figure 1D). AKT is also phosphorylated at AKT\textsuperscript{T308} in a PI3K-dependent manner by PDK and was not significantly augmented by everolimus treatment before or after anti-IgM treatment. However, PF-04691502 completely abrogated AKT\textsuperscript{T308} phosphorylation (Figure 1E). Together these data indicate that the same negative feedback loop involving mTORC2 is in operation in CLL cells but is circumvented by PF-04691502.

PF-04691502 reduces cell viability in CLL cells independently of prognostic markers

CLL samples were treated with PF-04691502 and viability assessed using annexin-V/PI staining (Supplementary Figure 2A). PF-04691502 reduced viability of CLL cells after 24, 48 and 72h hours (Figure 2A & 2B) with a mean IC\textsubscript{50} of 0.96\textmu M (median 0.65\textmu M), 0.32\textmu M and 0.25\textmu M, respectively. The same CLL samples treated with idelalisib did not reach its IC\textsubscript{50} value up to 40\textmu M (Figure 2A) in agreement with the literature.\textsuperscript{19,20} Normal B and T cells from age-matched controls were largely unaffected by PF-04691502 over a similar dose range. No significant differences in mean IC\textsubscript{50} values for PF-04691502 were observed between unmutated (U-CLL) and mutated (M-CLL) IGHV genes (Figure 2B), high and low ZAP-70 (>30%) (Figure 2C) or CD38 expression (>30%) (Figure 2D). However a trend for lower IC\textsubscript{50} values was observed in U-CLL compared to M-CLL. Furthermore, three CLL samples with 17p del (2/3 samples >70% 17p del by FISH) were as susceptible to PF-04691502-induced death as wildtype samples (Supplementary Figure 2B), indicating that PF-04691502 may also have activity independent of 17p del status.

Combination of isoform specific PBI inhibitors and an mTOR inhibitor mimic PF-04691502
PF-04691502 reduced viability of CLL cells to a greater extent compared to idelalisib. Therefore, we sought to determine whether we could replicate its efficacy using a combination of isoform-specific PI3K inhibitors including BYL719 (PI3Kα inhibitor), GSK2636771 (PI3Kβ inhibitor), idelalisib (PI3Kδ inhibitor), AS-605240 (PI3Kγ inhibitor) in combination with the mTOR inhibitor everolimus (mTORC1 inhibitor). Each inhibitor alone (1µM) reduced viability by no more than ~10% (Supplementary Figure 2C). This was in contrast to PF-04691502, which at the same concentration reduced CLL cell viability by >50%. The combination of all five selective inhibitors at 1µM significantly reduced CLL cell viability more than any of the inhibitors alone, albeit significantly less than PF-04691502 (p=0.004, n=11). Finally we showed that a combination of idelalisib with everolimus was significantly more efficacious than either agent alone (p=0.02 and p=0.01) (Supplementary Figure 2D) but significantly less than PF-04691502 (p=0.03). Together these data suggest that PF-04691502 likely achieves its robust killing effects through simultaneous inhibition of mTORC1, mTORC2 and PI3Kδ.

**PF-04691502 induces apoptosis in a caspase-dependent mechanism**

To determine the mechanism of death induced by PF-04691502, we first investigated expression of key pro-apoptotic BH3-only proteins Noxa, Puma, Bad, Bim and Bax, and anti-apoptotic Bcl-2 family proteins Mcl-1 and Bcl-2 which regulate apoptosis within CLL cells. Incubation with PF-04691502 (0.31-1.25µM) induced Noxa and Puma expression (protein and mRNA) in a dose-dependent manner (Figure 3A and data not shown). No significant changes were observed for Bim, Bad, Bcl-2 or Mcl-1 (data not shown). Basal pAKT\(^{3473}\) and pS6K\(^{7389}\) were inhibited by PF-04691502 as expected. In response to pro-apoptotic stimuli, Bax undergoes a conformational change and subsequently becomes inserted into the outer mitochondrial membrane where it facilitates cytochrome c release and subsequent apoptosis. Using the conformational change specific 6A7 antibody\(^{37}\) we showed that CLL cells incubated with PF-04691502 produced a marked increase in the active, mitochondrially-resident conformation of Bax (Figure 3B). Furthermore treatment of CLL cells with PF-04691502 (0.31-5µM) for 18 hours induced caspase-3 cleavage and subsequent appearance of the p85 cleaved sub-fragment of PARP (Figure 3C). To confirm PF-04691502 induced apoptosis of CLL cells in a caspase-dependent manner, we treated cells with the pan-caspase inhibitor ZVAD.fmk. ZVAD.fmk significantly prevented the PF-04691502 induced decrease in cell viability even at the highest concentrations of PF-04691502 (20µM) (p<0.001, n=7) (Figure 3D).

**PF-04691502 reduced viability of CLL cells in co-culture with stromal cells**

CLL cells are known to receive key survival signals from stromal cells in the bone marrow and lymph nodes, reducing CLL apoptosis and promoting drug resistance.\(^{12}\) Therefore, we investigated the
effect of PF-04691502 upon CLL cells co-cultured with human stromal fibroblast cells (HFFF2) which we have observed can provide anti-apoptotic signaling to CLL cells (manuscript in preparation). PF-04691502 significantly inhibited signaling induced by HFFF2 (Supplementary Figure 3A) and reduced CLL cell viability (p=0.016), thus showing its ability to overcome stromal support (Figure 3E). To preclude that its activity was due to a direct cytotoxic effect on the fibroblasts (Supplementary Figure 3B) we also performed “wash-out” experiments where PF-04691502 was added to the CLL cells for 1h and washed off prior to addition to the HFFF2 cells. Cell viability was still significantly reduced by PF-04691502 (p=0.016) and downstream signaling inhibited in this setting (Figure 3F, Supplementary Figure 3C).

**Dual PKB/mTOR inhibition decreases pro-survival BCR signaling**

Ligation of the CLL BCR by antigen/autoantigen is thought to primarily occur in the lymph nodes, acting to enhance CLL survival and resistance to chemotherapy. Antigen in lymph nodes may be present in both soluble and membrane bound forms. Therefore, we utilised both soluble and bead-immobilised anti-IgM to investigate the effect of PF-04691502 (2.5-2500nM) on BCR signaling. Analysis of downstream signaling showed that both the soluble (Figure 4A) and bead-immobilised (Figure 4B) anti-IgM induced strong activation of pAKT$^{S473/T308}$, pERK$^{T202/Y204}$, pS6K$^{T389}$ and pS6$^{S235/236}$ ribosomal subunit. PF-04691502 significantly inhibited pAKT$^{S473/T308}$ and pS6K$^{T389}$ in CLL samples following both soluble and immobilised anti-IgM treatment and at concentrations below maximum achievable plasma drug concentrations (100-200nM). pERK$^{T202/Y204}$ and pS6$^{S235/236}$ were significantly inhibited by PF-04691502 following soluble (Figure 4A) but not immobilised (Figure 4B) anti-IgM treatment. These data indicate that PF-04691502 inhibits PDK1-mediated pAKT$^{T308}$, mTORC1-induced pS6K$^{T389}$ and mTORC2-mediated pAKT$^{S473}$ activation. Furthermore activation of these BCR-signals with immobilised anti-IgM beads strongly protects CLL cells from apoptosis as indicated by a decrease in cleaved caspase-3 and PARP compared to the control, but was reversed upon treatment with PF-04691502 (Supplementary Figure 4A).

**PF-04691502 inhibits CXCL12 induced signaling and subsequent migration**

In vivo, CXCL12 signaling enables CLL cells to enter and become retained within protective lymph node microenvironments. Therefore, disruption of CXCL12/CXCR4 signaling provides an attractive therapeutic target. Here, CLL cells treated with CXCL12 (200ng/ml) for 10 minutes showed increased pAKT$^{S473}$, pS6K$^{T389}$ and pS6$^{S235/236}$ which was reversed following treatment with PF-04691502 (Figure 5A). In contrast, pERK$^{T202/Y204}$ was not affected by PF-04691502 pre-treatment, potentially due to downstream signalling from Syk/Ras being unaffected by PF-04691502. Next, we
determined the effect of PF-04691502 on CLL motility in an in vitro transwell migration assay. Treatment of CLL cells with PF-04691502 showed no significant effect on basal CLL motility, however CXCL12-induced CLL motility was significantly abrogated following pre-treatment with PF-04691502 for only 30 minutes (p=0.02 and p=0.025 at 1.25 and 2.5µM, respectively) (Figure 5B) and was not dependent on reduced expression of CXCR4 (Supplementary Figure 4B). These data indicate that PF-04691502 inhibits CXCL12 signalling and subsequent migration, which has potential importance for CLL cells accessing the protective lymph node microenvironment in vivo.

**PF-04691502 has efficacy in murine Eµ-TCL1 cells ex vivo**

Next, we examined whether PF-04691502 displayed activity against murine Eµ-TCL1 tumor cells, isolated and cultured ex vivo. Eµ-TCL1 tumor cells were isolated from the spleens of tumor-bearing mice and then treated with anti-IgM or CXCL12 in the presence or absence of PF-04691502 and the effects on downstream signaling investigated by immunoblotting. PF-04691502 substantially blocked signaling induced by both stimuli, reducing pAKT<sup>Thr856</sup>, pAKT<sup>Ser73</sup>, pS6K<sup>Thr42/44</sup> and pS6<sup>Ser235/236</sup> to below background levels, with lesser effects on pERK<sup>Thr202/Tyr204</sup> at 2.5-25nM PF-04691502 (Figure 6A and 6B). These effects translated into an ability of PF-04691502 to efficiently kill Eµ-TCL1 tumor cells (n=8 different tumors) (Figure 6C) and inhibit migration towards CXCL12 (Figure 6D). These data recapitulated those seen with primary human CLL cells above.

**In vivo efficacy of PF-04691502**

Finally, we explored the activity of PF-04691502 in vivo. Cohorts of mice were inoculated with Eµ-TCL1 tumor cells and when tumor was visible in the blood (approximately 21 days), mice were randomised to receive 5 or 10mg/kg/day PF-04691502 or vehicle control by oral gavage and the leukemic burden in the blood was monitored over the following 14 days (Figure 7A). After receiving the drug a small but significant lymphocytosis was observed which persisted for approximately 4-7 days. Subsequently, PF-04691502 elicited a marked reduction in leukemic burden compared to the vehicle control (p=0.0001), indicating a profound anti-tumor effect. Both drug doses demonstrated the same efficacy, indicating that the minimum effective dose was achieved. Fourteen days post treatment vehicle-recipient animals exhibited a terminal disease and were sacrificed alongside mice receiving 10mg/kg/day PF-04691502 and the effects of the drug on multiple tissues including the spleen, lymph nodes and bone marrow (Figure 7B-D) determined. Mice receiving 5 mg/kg/day were maintained on drug for survival experiments. Visual assessment and weighing of the spleen illustrated the ability of the drug to prevent tumor expansion at this site (Figure 7B and 7C); which was confirmed by enumerating the number of tumor cells (Figure 7D). In fact, no increase in splenic
mass was observed compared to normal healthy C57BL/6 mice, whereas vehicle-treated mice exhibited a 4-8 fold increase in splenic mass, alongside a tumor cell count an order of magnitude higher than PF-04691502 treated mice. Next, we examined the macroscopic appearance of the spleen using hematoxylin and eosin (H&E) staining (Supplementary Figure 5A). These images indicate that the Eμ-TCL1 leukemias destroy the typical splenic architecture, whereas this was largely prevented by PF-04691502 treatment. In addition to the spleen, we also observed similar effects of the drug reducing tumor expansion in the lymph nodes and bone-marrow (Figure 7D). Cumulatively, these effects significantly enhanced survival in 5 mg/kg/day-recipient animals (p<0.0001) (Supplementary Figure 5B). Furthermore, mice showed a small but significant reduction in normal B-cell number but no significant reduction in normal T-cell number (data not shown). These data indicate that PF-04691502 has substantial efficacy in vivo, warranting further investigation of dual PI3K/mTOR inhibitors for the treatment of CLL.

**DISCUSSION**

Treatment of CLL patients with ibrutinib and idelalisib have produced impressive clinical responses, however the agents are not curative and only suppress the disease. Therefore, identifying an agent that can purge CLL cells from the protective lymph node and bone marrow niches in combination with substantive tumor toxicity may prove essential for an eventual cure. Our results showed that PF-04691502 inhibited BCR and CXCL12 induced signaling, resulting in caspase-dependent apoptosis of CLL cells in vitro at nanomolar concentrations, whilst treatment of normal B and T cells resulted in little to no death. Caspase-dependency was confirmed with the pan-caspase inhibitor ZVAD.fmk and was preceded by the pro-apoptotic conformational change in Bax. Bax activation correlated with the induction of the BH3-only Bcl-2 family members Noxa and Puma suggesting activation of the intrinsic apoptotic pathway. However, since 17p del cases displayed equivalent sensitivity to PF-04691502 as wildtype samples, the pathway leading to Noxa and Puma induction after PF-04691502 treatment may be TP53-independent. The mechanism behind the Noxa and Puma induction is currently unknown and is the subject of our ongoing studies. PF-04691502 induced apoptosis independently of known prognostic markers, which is consistent with findings with idelalisib in CLL. However, an intriguing finding was the enhanced apoptotic potency of PF-04691502 in comparison to idelalisib. This increased cytotoxicity against CLL cells by PF-04691502 may be due to inhibition of more than one PI3K isoform or more likely due to the co-inhibition of PI3K and mTORC1/2. Evidence in mantle cell lymphoma to support this has shown constitutive PI3Kα signaling limits the efficacy of PI3Kδ selective inhibitors. Functional redundancy between PI3K isoforms in the survival of neutrophils has previously been shown, therefore it may be theorized that in CLL cells other PI3K
isoforms may compensate for the selective inhibition of PI3Kδ with idelalisib, resulting in lower levels of cytotoxicity with this drug. However the γ/δ inhibitor IPI-145 did not increase CLL cell apoptosis more than idelalisib in vitro.\textsuperscript{44} In contrast, the dual PI3Kα/γ inhibitor PIK90 and the pan-PI3K inhibitor NVP-BKM120 (Buparlisib) induce substantially more CLL cell apoptosis,\textsuperscript{23,45} than single isoform inhibitors.\textsuperscript{19} The potential caveat to inhibition of more than a single PI3K isoform is the possibility of greater toxicity to normal tissues. However, a number of pan-PI3K inhibitors and dual PI3K/mTOR inhibitors are currently progressing through clinical trials for various malignancies with promising results.\textsuperscript{46} Interestingly, long-term PI3Kα inhibition was not detrimental to mice and in fact protected against a reduction in insulin sensitivity, glucose tolerance and fat accumulation.\textsuperscript{47} During our study we combined inhibitors that targeted specific isoforms of PI3K and mTOR; replicating our findings with PF-04691502. Although combining the PI3Kα/β/δ/γ inhibitors or idelalisib with the mTOR inhibitor everolimus induced substantial apoptosis, PF-04691502 alone still induced significantly more. This may be because everolimus inhibits predominately mTORC1, whilst PF-04691502 inhibits both mTORC1 and mTORC2, which is essential to inhibit the positive feedback and subsequent phosphorylation of AKT\textsuperscript{579}. However, these data suggest that an mTORC1 inhibitor, and maybe more importantly a dual mTORC1/2 inhibitor, in combination with idelalisib may be more therapeutically beneficial in the treatment of CLL than PI3K inhibition alone.

Ligation of the BCR occurs primarily in the protective lymph node microenvironment\textsuperscript{48} and is thought to be crucial for survival of the malignant clone.\textsuperscript{40} Furthermore, CXCL12 induces migration of the CLL cells from the periphery into the lymph node promoting their retention within protective microenvironments.\textsuperscript{12} CXCL12/CXCR4 signaling has previously been shown to inhibit spontaneous cell death and chemotherapy-induced apoptosis.\textsuperscript{49} Therefore, our finding that PF-04691502 could overcome pro-survival anti-IgM induced signaling and substantially inhibit CXCL12 signaling and subsequent CLL migration is of clear importance. This is also in agreement with what has been described for idelalisib.\textsuperscript{20} These results indicate that PF-04691502 may have similar clinical characteristics to other kinase inhibitors, where the inhibition of BTK, PI3Kδ or SYK results in reduced interaction of CLL cells with its protective microenvironments, re-distribution of the tumor cells from tissues to the blood and some cellular toxicity.\textsuperscript{10,50} This resulted in clinical activity whereby patients undergo rapid lymph node shrinkage and lymphocytosis within weeks of treatment initiation.\textsuperscript{7,11,20} Due to the relatively low toxicity of these agents alone on CLL cells, combining them with Bcl-2 antagonists (ABT-199) has been proposed. However, given the trend for greater Mcl-1 expression in CLL patient lymph nodes,\textsuperscript{51} which is regulated by microenvironmental factors through PI3K, PI3K inhibition may have greater efficacy. This raises the question as to whether targets downstream of
PI3K, such as AKT, are equally tractable. However, current data suggest not, as CLL cells treated with AKT inhibitors (MK2206 and AZD5363) required concentrations in excess of 10µM to elicit relatively small amounts of apoptosis and clinical trials have stopped recruiting (NCT01369849).

Tumor cell redistribution was also evident in the Eµ-TCL1 model with a transient lymphocytosis seen in the blood concomitant with reduced tumor load in the secondary lymphoid organs and bone marrow upon PF-04691502 treatment. Such lymphocytosis is likely a consequence of reduced chemokine receptor expression or signal inhibition. Interestingly, although PF-04691502 treatment prevented accumulation of tumor in the spleen and caused protection of the global splenic architecture, tumor was still evident, even in the presence of PF-04691502. Therefore, these tumor deposits likely reflect treatment-resistant reservoirs, which require additional interventions with other treatment modalities. This is the basis for our on-going studies.

The results from this study show that simultaneous inhibition of all four class 1 PI3K isoforms in combination with the inhibition of mTOR kills CLL cells more potently than selective PI3Kδ inhibition alone. The data generated with systems mimicking ongoing BCR stimulation and stromal support indicates its ability to overcome protective microenvironment signalling in vivo. These results are supported by in vivo experimentation using the Eµ-TCL1 mouse model that further indicates that PF-04691502 may prove therapeutically useful for the treatment of CLL. Further studies are now required to investigate its key modes of action and explore its utility in combination with other treatment modalities.

**Acknowledgements:** We thank Pfizer Inc. for providing pure substance for this study (PF-04691502), Leukaemia and Lymphoma Research (12044) and Kay Kendall (KKL687) for supporting this work, the patients for supplying tissue and the infrastructure support from a CR-UK centre grant (C34999/A18087). We thank Dr Duriez for the provision of Annexin V-FITC. We would like to thank Dr Egle, Dr Pekarsky and Professor Croce for the provision of the Eµ-TCL-1 mouse model and Prof Thomas for the HFFF2 cells. Finally, we thank Mr Tracy and Mrs Henderson for biobanking and characterisation of the CLL samples used in this study (LJR grant 12021, ECMC C24563/A15581) and Dr Gobessi and Prof. Efremov for advice on the use of the Eµ-Tcl-1 model.

**Author contributions:** MDB, MJC, JCS, MSC and AJS designed research and wrote the manuscript. MDB, MJC ML, LDS, MH, KLC, TT, MR, LM, SD and SM performed research and analyzed data. FF obtained consent from patients, blood samples and collated and analysed clinical data. AD provided
patients and clinical data. FS, PWMJ, GP provided critical review, suggested experiments and edited the paper.

**Conflict of interests:** The authors state that there are no conflicts of interest.

**References**


FIGURE LEGENDS

**Figure 1. Inhibition of mTOR augments AKT signaling in CLL which can be overcome by a dual PI3K/mTOR inhibitor.** (A) CLL cells were pre-treated with Everolimus (1 µM) or PF-04691502 (1 µM) for 2.5 hours prior to treatment with soluble anti-IgM (IgM) for 15 minutes. Immunoblotting was performed for phosphorylated AKT (pAKT\(^{S473}\)), S6 kinase (pS6K\(^{T389}\)) and S6 (pS6 ribosomal subunit\(^{S235/236}\)). Bcl-2 was used as a loading control. Graphs (B-E) represent the fold change in pAKT\(^{S473}\), pS6K\(^{T389}\), pS6\(^{S235/236}\) and AKT\(^{T308}\) compared to the untreated basal control following the various treatments described above (n=7, 6, 7 and 5 respectively). * represents p<0.05. Error bars represent SEM.

**Figure 2. PF-04691502 reduces cell viability of CLL cells independently of prognostic markers.** (A) CLL samples (n=25) and normal B (CD19\(^{+}\)) and T cells (CD3\(^{+}\)) (n=5) were treated in the presence or absence of PF-04691502 (0.0049-40µM) for 24 hours. Cell viability was calculated using AnnexinV/PI assays and measured by flow cytometry. For comparison a proportion of the same CLL samples were treated with idelalisib (0.0049-40µM) (n=12). (B) CLL samples (n=6) were treated with PF-04691502 (0.0025-2.5µM) for 24-72h in a small cohort of 6 patients (3 low IC\(_{50}\) and 3 high IC\(_{50}\) at 24h). (C-E) Correlation of the response to PF-04691502 with prognostic markers IGHV (n=21), ZAP70 (n=23) and CD38 (n=23). Error bars represent SEM.

**Figure 3. PF-04691502 induces the intrinsic apoptosis pathway following PI3K/mTOR pathway inhibition.** Immunoblotting was utilised to show (A) Expression of the Bcl-2 family of pro-apoptotic proteins namely Noxa and Puma in resting non-activated cells. pAKT\(^{S473}\) and pS6K\(^{T389}\) were used to confirm PF-04691502 treatment (18h) had inhibited the PI3K/mTOR pathway. HSC70 was the loading control. The figure is representative of 9 independent experiments. (B) BAX conformational change was investigated in the presence or absence of PF-04691502, immunoprecipitation with the BAX 6A7 was performed as described (Supplementary methods). IgH and IgL were included to confirm identical quantities of antibody were used for the immunoprecipitation. Blot is representative of 4 independent experiments. (C) Cleavage of caspase-3 and its substrate PARP (marker of apoptosis), representative blot of 10 independent experiments. (D) CLL samples (n=7) were treated with PF-04691502 as above but with or without the pan-caspase inhibitor ZVAD.fmk and analysed by flow cytometry for Annexin V/PI negativity. (E) Stromal fibroblasts (HFFF2) were co-cultured with CLL cells and the whole well treated in the presence or absence of continuous PF-04691502 (2.5µM) for 24h. CLL cells were removed by pipetting (Supplementary Figure 3D) or scraping (Figure 3E) and cell viability analysed using Annexin V/PI analysis by flow cytometry (n=?). (F) The assay was performed as (E) except that the CLL cells were pre-treated for 1 hours with PF-04691502 prior to drug washed out and the treated CLL cells were plated into wells containing stromal fibroblasts (n=7). Error bars represent SEM. (Method in supplementary data). No difference was observed between scraping all cells or washing off only the CLL cells (compare Figure 3E and Supplementary Figure 3D).

**Figure 4. PF-04691502 inhibits anti-IgM induced signaling**
CLL cells were treated with (A) soluble anti-IgM (n=9) and (B) immobilised anti-IgM beads (n=5) prior to evaluation of downstream signalling in the presence and absence of PF-04691502 (0.0025-2.5µM) by immunoblot analysis. Representative cases are shown. CLL cells were treated for an hour with PF-04691502 prior to soluble/immobilised anti-IgM addition. pAKT<sup>T308</sup> and pS6K<sup>T389</sup> were used as markers of PI3K signalling, pAKT<sup>S473</sup> and pS6<sup>S235/236</sup> were used as markers of mTOR signalling and pERK<sup>T202/Y204</sup> was used as a marker of MAPK signalling.

**Figure 5.** PF-04691502 inhibits CXCL12 signalling and subsequent migration

(A) CLL cells were treated with 200 ng/ml CXCL12 for the times indicated in the presence or absence of PF-04691502 (0.25-2.5µM). PF-04691502 was added 30 minutes prior to the addition of CXCL12. Immunoblotting was performed pAKT<sup>S473</sup>, pS6K<sup>T389</sup>, pS6<sup>S235/236</sup>, pERK<sup>T202/Y204</sup>, total proteins and the loading control Bcl-2 were investigated, immunoblot representative of 6 independent experiments. (B) Using a transwell migration assay we evaluated the migration of CLL cells towards 200ng/ml CXCL12 in the presence or absence of PF-04691502 (1.25-2.5µM). Flow cytometry was used to count the number of cells which had passed through the transwell filter (n=5). Error bars represent SEM. (Method in supplementary data).

**Figure 6.** PF-04691502 inhibits anti-IgM and CXCL12 induced signalling in Eµ-TCL-1 murine cells. 

Eµ-TCL-1 cells were removed from mice and grown in vitro. Eµ-TCL-1 cells were treated with (A) anti-IgM (5-15mins) or (B) 200ng/ml CXCL12 in the presence or absence of PF-04691502 (0.0025-2.5µM) and the effects on downstream signalling (pAKT<sup>T308</sup>, pAKT<sup>S473</sup>, pS6K<sup>T389</sup>, pS6<sup>S235/236</sup> and pERK<sup>T202/Y204</sup>) investigated by immunoblotting. HSC70 was used as a loading control. (C) Viability of Eµ-TCL-1 cells by PF-04691502 was evaluated by AnnexinV/PI assays and represented as percentage viable cells. (D) Migration was performed as previously described in Figure 5B. Error bars represent SEM.

**Figure 7.** The effect of PF-04691502 in the Eµ-TCL-1 mouse model

Mice inoculated with Eµ-TCL-1 tumor cells were treated by oral gavage with 5 or 10mg/kg/d PF-04691502 or placebo control over 14 days of continual treatment once the emergence of a leukemic phase occurred at day 21 (depicted by the arrow). (A) Peripheral leukemic (CD5<sup>+</sup>CD220<sup>+</sup>) cell number was evaluated by flow cytometry in the presence of PF-04691502 or the vehicle control. (B) Illustration of the spleen sizes from mice treated with 10mg/kg/day PF-04691502 or vehicle control compared to the WT mouse C57Bl/6. (C) Represents the spleen weights from (B). (D) Leukemic cell number was also investigated in various organs including spleens (SPL), lymph nodes (LN) and bone marrow (BM) following treatment with PF-04691502 or the vehicle control. Error bars represent SEM.
Figure 2

(A) Effect of PF-04691502 on % of Control (PI/Annexin V-) cells in CLL, Normal CD3, and Normal CD19 cells. The concentration response curves for these cell types are shown.

(B) Dose-response curves for PF-04691502 at different time points (72 hrs, 48 hrs, 24 hrs).

(C) Scatter plot showing IC50 values for U-CLL and M-CLL.

(D) Scatter plot showing IC50 values for ZAP-70 +ve and ZAP-70 -ve.

(E) Scatter plot showing IC50 values for CD38 +ve and CD38 -ve.

Statistical significance:
- U-CLL vs M-CLL: P = 0.09
- ZAP-70 +ve vs ZAP-70 -ve: P = 0.24
- CD38 +ve vs CD38 -ve: P = 0.47
**Figure 3**

**A**

<table>
<thead>
<tr>
<th>PF-04691502 (μM)</th>
<th>0</th>
<th>0.31</th>
<th>0.63</th>
<th>1.25</th>
</tr>
</thead>
<tbody>
<tr>
<td>pAKT (Ser473)</td>
<td>0.36</td>
<td>0.12</td>
<td>0.16</td>
<td>0.09</td>
</tr>
<tr>
<td>pAKT(Ser473)/HSC70</td>
<td>0.76</td>
<td>0.46</td>
<td>0.62</td>
<td>0.52</td>
</tr>
<tr>
<td>AKT/HSC70</td>
<td>0.69</td>
<td>0.31</td>
<td>0.34</td>
<td>0.29</td>
</tr>
<tr>
<td>pS6 kinase (Thr389)</td>
<td>0.87</td>
<td>0.42</td>
<td>0.8</td>
<td>0.73</td>
</tr>
<tr>
<td>S6 kinase</td>
<td>0.87</td>
<td>0.42</td>
<td>0.8</td>
<td>0.73</td>
</tr>
<tr>
<td>S6 kinase/HSC70</td>
<td>0.73</td>
<td>0.41</td>
<td>0.81</td>
<td>0.73</td>
</tr>
<tr>
<td>NOXA</td>
<td>0.36</td>
<td>0.98</td>
<td>1.41</td>
<td>1.21</td>
</tr>
<tr>
<td>NOXA/HSC70</td>
<td>0.36</td>
<td>0.98</td>
<td>1.41</td>
<td>1.21</td>
</tr>
<tr>
<td>PUMA</td>
<td>0.55</td>
<td>0.83</td>
<td>1.03</td>
<td>1.02</td>
</tr>
<tr>
<td>PUMA/HSC70</td>
<td>0.55</td>
<td>0.83</td>
<td>1.03</td>
<td>1.02</td>
</tr>
<tr>
<td>HSC70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>IP: BAX</th>
<th>WCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.25</td>
</tr>
<tr>
<td>0.52</td>
<td>1.21</td>
</tr>
<tr>
<td>Bax/IgH</td>
<td></td>
</tr>
</tbody>
</table>

**C**

<table>
<thead>
<tr>
<th>PF-04691502 (μM)</th>
<th>0</th>
<th>0.31</th>
<th>0.63</th>
<th>1.25</th>
<th>2.5</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARP</td>
<td>0.08</td>
<td>0.17</td>
<td>0.37</td>
<td>0.43</td>
<td>0.74</td>
<td>0.8</td>
</tr>
<tr>
<td>Ratio p85/Total PARP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caspase 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cleaved Caspase 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cleaved Caspase 3/HSC70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSC70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**D**

![Graph showing concentration vs. % of control PI/Annexin V-ve cells](image)

**E**

**Continuous Exposure**

- **PF-04691502**
- **PF-04691502 + ZVAD**

**F**

**Wash out**

- **PF-04691502**
- **PF-04691502**

*NS* = Not Significant

* = Significant difference

** = Very significant difference
Figure 5

(A) Western blot analysis of various proteins under different conditions.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Protein</th>
<th>Concentration (µM)</th>
<th>Value 1</th>
<th>Value 2</th>
<th>Value 3</th>
<th>Value 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCL12</td>
<td>pAKT (Ser473)</td>
<td>0</td>
<td>0.24</td>
<td>0.3</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>pAKT(Ser473)/HSC70</td>
<td>0</td>
<td>0.24</td>
<td>0.3</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>AKT</td>
<td>0</td>
<td>0.66</td>
<td>0.85</td>
<td>0.73</td>
<td>0.78</td>
</tr>
<tr>
<td></td>
<td>AKT/HSC70</td>
<td>0.66</td>
<td>0.85</td>
<td>0.73</td>
<td>0.78</td>
<td>0.84</td>
</tr>
<tr>
<td></td>
<td>pS6 kinase (Thr389)</td>
<td>0</td>
<td>0.23</td>
<td>0.11</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>pS6 kinase(Thr389)/HSC70</td>
<td>0</td>
<td>0.23</td>
<td>0.11</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>S6 kinase</td>
<td>0.66</td>
<td>1.04</td>
<td>1.15</td>
<td>1.16</td>
<td>1.09</td>
</tr>
<tr>
<td></td>
<td>S6 kinase/HSC70</td>
<td>0.66</td>
<td>1.15</td>
<td>1.16</td>
<td>1.09</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>pS6 ribosomal subunit (Ser235/236)</td>
<td>0.85</td>
<td>0.58</td>
<td>0.34</td>
<td>0.31</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>pS6 ribosomal subunit(Ser235/236)/HSC70</td>
<td>0</td>
<td>0.58</td>
<td>0.34</td>
<td>0.31</td>
<td>0.32</td>
</tr>
<tr>
<td></td>
<td>S6 ribosomal subunit</td>
<td>0</td>
<td>0.92</td>
<td>0.92</td>
<td>0.89</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>S6 ribosomal subunit/HSC70</td>
<td>0</td>
<td>0.92</td>
<td>0.92</td>
<td>0.89</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>pERK (Thr202/Tyr204)</td>
<td>0</td>
<td>0.49</td>
<td>0.53</td>
<td>0.54</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>pERK(Thr202/Tyr204)/HSC70</td>
<td>0</td>
<td>0.49</td>
<td>0.53</td>
<td>0.54</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>ERK</td>
<td>0.66</td>
<td>1.06</td>
<td>1.09</td>
<td>1.15</td>
<td>1.14</td>
</tr>
<tr>
<td></td>
<td>ERK/HSC70</td>
<td>1.06</td>
<td>1.09</td>
<td>1.15</td>
<td>1.14</td>
<td>1.12</td>
</tr>
</tbody>
</table>

(B) Bar graph showing the migration of cells under different conditions.

- Migrated Cells Fold Change (CD5+ve/CD19+ve)
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

Matthew D. Blunt, Matthew J. Carter, Marta Larrayoz, Lindsay D. Smith, Maria Aguilar-Hernandez, Kerry L. Cox, Thomas Tipton, Mark Reynolds, Sarah Murphy, Elizabeth Lemm, Samantha Dias, Andrew Duncombe, Jonathan C. Strefford, Peter W.M. Johnson, Francesco Forconi, Freda K. Stevenson, Graham Packham, Mark S. Cragg and Andrew J. Steele